Linda Ibatá
Research Subjects
Linda Ibatá has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Susan Martínez
Epidemiology Department, Epithink Health Consulting, Bogotá, Colombia
10 shared publications - Angela María Londoño-García
CES University Medellin Colombia
7 shared publications - Juan Raúl Castro-Ayarza
Dermatology Postgraduate Program, Faculty of Medicine, National University of Colombia, Bogota, Colombia
7 shared publications - Julieth Carolina Castillo
Epidemiology Department, Epithink Health Consulting, Bogotá, Colombia
6 shared publications - Paola Jimena Cárdenas Rojas
Medicarte IPS Bogotá Colombia
6 shared publications - Enrique Salvador Rivas Zaldívar
Research Department, Dermatological Medical Center DERMOS, Ciudad de Guatemala, Guatemala
5 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Clinical practice guideline for psoriasis management in Latin America
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Open AccessClinical practice guideline for psoriasis management in Latin America
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- 10 July 2026
- Published by Wiley in International Journal of Dermatology
Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image
- Open Access
- 1 July 2026
- Published by Wiley in JCSM Communications
- Vol. 9 (2)
Expert Consensus on Diagnosis and Management of Secondary Sarcopenia in Adults in Colombia: A Modified Delphi Study
Background: Secondary sarcopenia driven by chronic disease, acute illness, immobilization, malnutrition or treatment‐related factors contributes to functional decline, falls, disability, readmission and mortality. In Colombia, uneven access to body composition assessment, nutrition services and rehabilitation limits timely recognition and management. Methods: We conducted a modified Delphi expert consensus to develop Colombia‐focused recommendations for adults with suspected or confirmed secondary sarcopenia. Seven invited experts from geriatrics, intensive care medicine, clinical nutrition, physiotherapy, rehabilitation and surgery accepted participation and completed the consensus process. A structured evidence review from 2015 to 2025 informed 90 candidate statements across screening, diagnosis, nutrition, therapeutic exercise and follow‐up. Statements were rated using a 5‐point Likert scale. For each statement, a weighted consensus score was calculated as the sum of Likert scores divided by the maximum possible score and multiplied by 100. A weighted score of 70% or higher was prespecified as the approval threshold. Results: The 90 candidate statements were reduced to 50 final recommendations, representing a net reduction of 40 statements. The recommendations were organized into six thematic tables and address screening triggers, stepwise diagnostic confirmation, early interdisciplinary management, individualized nutrition strategies, structured multicomponent exercise and longitudinal reassessment using consistent baseline measures. Conclusions: This evidence‐informed expert consensus provides practical recommendations for screening, diagnosis, treatment and follow‐up of secondary sarcopenia in adults in Colombia. The document is intended as expert consensus guidance rather than a formal clinical practice guideline. Selected elements may be relevant to settings with similar access constraints, but external validation is required.
- 1 July 2026
- Published by Wiley in JCSM Communications
- Vol. 9 (2)
Open AccessExpert Consensus on Diagnosis and Management of Secondary Sarcopenia in Adults in Colombia: A Modified Delphi Study
Background: Secondary sarcopenia driven by chronic disease, acute illness, immobilization, malnutrition or treatment‐related factors contributes to functional decline, falls, disability, readmission and mortality. In Colombia, uneven access to body composition assessment, nutrition services and rehabilitation limits timely recognition and management. Methods: We conducted a modified Delphi expert consensus to develop Colombia‐focused recommendations for adults with suspected or confirmed secondary sarcopenia. Seven invited experts from geriatrics, intensive care medicine, clinical nutrition, physiotherapy, rehabilitation and surgery accepted participation and completed the consensus process. A structured evidence review from 2015 to 2025 informed 90 candidate statements across screening, diagnosis, nutrition, therapeutic exercise and follow‐up. Statements were rated using a 5‐point Likert scale. For each statement, a weighted consensus score was calculated as the sum of Likert scores divided by the maximum possible score and multiplied by 100. A weighted score of 70% or higher was prespecified as the approval threshold. Results: The 90 candidate statements were reduced to 50 final recommendations, representing a net reduction of 40 statements. The recommendations were organized into six thematic tables and address screening triggers, stepwise diagnostic confirmation, early interdisciplinary management, individualized nutrition strategies, structured multicomponent exercise and longitudinal reassessment using consistent baseline measures. Conclusions: This evidence‐informed expert consensus provides practical recommendations for screening, diagnosis, treatment and follow‐up of secondary sarcopenia in adults in Colombia. The document is intended as expert consensus guidance rather than a formal clinical practice guideline. Selected elements may be relevant to settings with similar access constraints, but external validation is required.
- Open Access
- 8 July 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (7) , 1015
PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis
PARP inhibitors (PARPi), alone or in combination with androgen receptor signaling inhibitors (ARSi), have shown clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), particularly in tumors with homologous recombination repair (HRR) gene alterations. Recent data from the TALAPRO-2 trial complete the current evidence on PARPi–ARSi combination strategies in this setting. Background/Objectives: To evaluate the efficacy and safety of PARPi-based therapies—monotherapy and combination with ARSi—in patients with mCRPC, focusing on molecular subgroups defined by DNA repair alterations. Methods: We conducted a systematic review and meta-analysis of phase III randomized controlled trials (RCTs) assessing PARPi as monotherapy or in combination with ARSi. Searches were performed in PubMed, EMBASE, the Cochrane Library, and oncology conference proceedings up to February 2025. Outcomes included radiographic progression-free survival (rPFS), overall survival (OS), second progression-free survival (PFS2), and grade ≥3 adverse events (AEs). Data were pooled using a random-effects model, with subgroup analyses by DNA repair status. Results: Five RCTs (n = 2921) were I confirmincluded: three on combination therapy (n = 2271) and two on monotherapy (n = 650). Combination therapy improved rPFS in the ITT (HR = 0.64; 95% CI: 0.56–0.74), HRRm (HR = 0.55; 95% CI: 0.44–0.68), and BRCAm (HR = 0.33; 95% CI: 0.18–0.58) subgroups. OS was also improved in the ITT (HR = 0.80; 95% CI: 0.70–0.92), HRRm (HR = 0.68; 95% CI: 0.55–0.83), and BRCAm (HR = 0.54; 95% CI: 0.34–0.85) groups. No benefit was observed in non-HRRm patients. PFS2 favored combination therapy (HR = 0.77; 95% CI: 0.64–0.91). Grade ≥3 AEs were more frequent (RR = 1.44; 95% CI: 1.20–1.73). Monotherapy improved rPFS in ITT (HR = 0.46; 95% CI: 0.20–0.81) and BRCAm (HR = 0.33; 95% CI: 0.15–0.75); OS benefit was seen only in BRCAm (HR = 0.73; 95% CI: 0.57–0.95). Conclusions: PARPi therapies improve outcomes mainly in HRR- and BRCA-mutated mCRPC. Molecular selection is key to optimizing benefit and minimizing toxicity. Further research on the activity of PARPi combinations in non-HRR mutated mCRPC is needed to better understand the underlying mechanisms of efficacy.
- 8 July 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (7) , 1015
Open AccessPARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis
PARP inhibitors (PARPi), alone or in combination with androgen receptor signaling inhibitors (ARSi), have shown clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), particularly in tumors with homologous recombination repair (HRR) gene alterations. Recent data from the TALAPRO-2 trial complete the current evidence on PARPi–ARSi combination strategies in this setting. Background/Objectives: To evaluate the efficacy and safety of PARPi-based therapies—monotherapy and combination with ARSi—in patients with mCRPC, focusing on molecular subgroups defined by DNA repair alterations. Methods: We conducted a systematic review and meta-analysis of phase III randomized controlled trials (RCTs) assessing PARPi as monotherapy or in combination with ARSi. Searches were performed in PubMed, EMBASE, the Cochrane Library, and oncology conference proceedings up to February 2025. Outcomes included radiographic progression-free survival (rPFS), overall survival (OS), second progression-free survival (PFS2), and grade ≥3 adverse events (AEs). Data were pooled using a random-effects model, with subgroup analyses by DNA repair status. Results: Five RCTs (n = 2921) were I confirmincluded: three on combination therapy (n = 2271) and two on monotherapy (n = 650). Combination therapy improved rPFS in the ITT (HR = 0.64; 95% CI: 0.56–0.74), HRRm (HR = 0.55; 95% CI: 0.44–0.68), and BRCAm (HR = 0.33; 95% CI: 0.18–0.58) subgroups. OS was also improved in the ITT (HR = 0.80; 95% CI: 0.70–0.92), HRRm (HR = 0.68; 95% CI: 0.55–0.83), and BRCAm (HR = 0.54; 95% CI: 0.34–0.85) groups. No benefit was observed in non-HRRm patients. PFS2 favored combination therapy (HR = 0.77; 95% CI: 0.64–0.91). Grade ≥3 AEs were more frequent (RR = 1.44; 95% CI: 1.20–1.73). Monotherapy improved rPFS in ITT (HR = 0.46; 95% CI: 0.20–0.81) and BRCAm (HR = 0.33; 95% CI: 0.15–0.75); OS benefit was seen only in BRCAm (HR = 0.73; 95% CI: 0.57–0.95). Conclusions: PARPi therapies improve outcomes mainly in HRR- and BRCA-mutated mCRPC. Molecular selection is key to optimizing benefit and minimizing toxicity. Further research on the activity of PARPi combinations in non-HRR mutated mCRPC is needed to better understand the underlying mechanisms of efficacy.
- Open Access
- 7 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (4)
Consenso latino‐americano sobre redução gradual da terapia biológica na psoríase
- 7 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (4)
Open AccessConsenso latino‐americano sobre redução gradual da terapia biológica na psoríase
- Open Access
- 18 June 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (4) , 501134
Latin American consensus on tapering of biological therapy in psoriasis
- 18 June 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (4) , 501134
Open AccessLatin American consensus on tapering of biological therapy in psoriasis
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Consenso latino‐americano sobre classificação da gravidade da psoríase
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 539-547
Open AccessConsenso latino‐americano sobre classificação da gravidade da psoríase
- Open Access
- 29 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 539-547
Latin American consensus on psoriasis severity classification
- 29 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 539-547
Open AccessLatin American consensus on psoriasis severity classification
- Open Access
- 13 December 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Diagnóstico y tratamiento de la dermatitis atópica en Colombia. Actualización de la guía de práctica clínica
Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel altamente prevalente que afecta de manera negativa la calidad de vida de los pacientes y puede asociarse con comorbilidades sistémicas y afectación psicosocial. Se requiere la actualización de las guías de diagnóstico y tratamiento adecuado de la población y del contexto sanitario local. Objetivo: Esta actualización de la guía de práctica clínica (GPC), de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma), proporciona recomendaciones basadas en la evidencia para la evaluación y el manejo de la DA en Colombia, con un enfoque específico en tratamientos sistémicos, tópicos y terapias coadyuvantes, así como la gravedad y la gestión del riesgo. Estas recomendaciones están dirigidas a profesionales de la salud, tomadores de decisiones y pacientes. Métodos: Para desarrollar esta guía, se conformó un panel multidisciplinario de expertos y se llevó a cabo un proceso riguroso de revisión sistemática de la literatura para responder preguntas clínicas específicas. La certeza en la evidencia y la fuerza de las recomendaciones se evaluaron utilizando el enfoque GRADE (Grading of Recommendations Assessment, Development and Evaluation, por sus siglas en inglés). Resultados: El panel de expertos alcanzó consenso en once recomendaciones y nueve puntos de buena práctica para la atención de personas con DA. La revisión de la evidencia destaca la eficacia de crisaborol tópico, dupilumab, abrocitinib y upadacitinib en el manejo de la DA, con recomendaciones específicas para su uso en diferentes poblaciones. Se incluyen además recomendaciones para la descolonización de reservorios, la inmunoterapia con alérgenos y la restricción alimentaria, así como para la gestión del riesgo en el uso de terapias biológicas e inhibidores de las janocinasas (JAK, por sus siglas en inglés). Conclusiones: Esta guía proporciona recomendaciones actualizadas y basadas en la evidencia para el manejo integral de la DA en Colombia, considerando las necesidades específicas de adultos y niños. Se alienta a los profesionales de la salud a utilizar estas recomendaciones para optimizar la atención del paciente y mejorar los resultados clínicos.
- 13 December 2024
- Published by Asociacion Colombiana de Dermatologia y Cirugia Dermatologica in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Open AccessDiagnóstico y tratamiento de la dermatitis atópica en Colombia. Actualización de la guía de práctica clínica
Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel altamente prevalente que afecta de manera negativa la calidad de vida de los pacientes y puede asociarse con comorbilidades sistémicas y afectación psicosocial. Se requiere la actualización de las guías de diagnóstico y tratamiento adecuado de la población y del contexto sanitario local. Objetivo: Esta actualización de la guía de práctica clínica (GPC), de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma), proporciona recomendaciones basadas en la evidencia para la evaluación y el manejo de la DA en Colombia, con un enfoque específico en tratamientos sistémicos, tópicos y terapias coadyuvantes, así como la gravedad y la gestión del riesgo. Estas recomendaciones están dirigidas a profesionales de la salud, tomadores de decisiones y pacientes. Métodos: Para desarrollar esta guía, se conformó un panel multidisciplinario de expertos y se llevó a cabo un proceso riguroso de revisión sistemática de la literatura para responder preguntas clínicas específicas. La certeza en la evidencia y la fuerza de las recomendaciones se evaluaron utilizando el enfoque GRADE (Grading of Recommendations Assessment, Development and Evaluation, por sus siglas en inglés). Resultados: El panel de expertos alcanzó consenso en once recomendaciones y nueve puntos de buena práctica para la atención de personas con DA. La revisión de la evidencia destaca la eficacia de crisaborol tópico, dupilumab, abrocitinib y upadacitinib en el manejo de la DA, con recomendaciones específicas para su uso en diferentes poblaciones. Se incluyen además recomendaciones para la descolonización de reservorios, la inmunoterapia con alérgenos y la restricción alimentaria, así como para la gestión del riesgo en el uso de terapias biológicas e inhibidores de las janocinasas (JAK, por sus siglas en inglés). Conclusiones: Esta guía proporciona recomendaciones actualizadas y basadas en la evidencia para el manejo integral de la DA en Colombia, considerando las necesidades específicas de adultos y niños. Se alienta a los profesionales de la salud a utilizar estas recomendaciones para optimizar la atención del paciente y mejorar los resultados clínicos.
- Open Access
- 26 September 2024
- Published by Instituto Mexicano del Seguro Social in Nefrología Latinoamericana
- Vol. 21 (2) , 032-041
Urgent-start peritoneal dialysis for patients with end-stage renal disease. A health technology assessment
Objective: To analyze the available evidence on the relevant clinical and economic aspects of urgent-start peritoneal dialysis (US-PD) compared to urgent-sta...
- 26 September 2024
- Published by Instituto Mexicano del Seguro Social in Nefrología Latinoamericana
- Vol. 21 (2) , 032-041
Open AccessUrgent-start peritoneal dialysis for patients with end-stage renal disease. A health technology assessment
Objective: To analyze the available evidence on the relevant clinical and economic aspects of urgent-start peritoneal dialysis (US-PD) compared to urgent-sta...